Mn2", Ca2', and Fe2+ substitute for Mg2e to various extents in in vitro FeMo-co synthesis, whereas Ca2+ is ineffective in substrate reduction by nitrogenase. The observed differences in the nucleotide and divalent cation specificities suggest a role(s) for the nucleotide and divalent cation in in vitro FeMo-to synthesis that is distinct from their role(s) in substrate reduction.
Nitrogenase catalyzes the reductant-and ATP-dependent reduction of N2 to NH4' during biological nitrogen fixation.
Nitrogenase is composed of two protein components: dinitrogenase (component I or molybdenum-iron protein) and dinitrogenase reductase (component II or Fe protein) (1, 5) . Dinitrogenase reductase, the nifH gene product, serves as a specific electron donor for dinitrogenase, the a2132 tetramer of the products of nifD and nifK. The electrons transferred to dinitrogenase are channeled to the iron-molybdenum cofactor (FeMo-co), the site of substrate reduction (6, 17) .
During nitrogenase turnover, two molecules of MgATP bind to dinitrogenase reductase, inducing a conformational change that is proposed to be necessary for electron transfer to dinitrogenase. The transfer of a single electron is accompanied by the hydrolysis of 2MgATP to 2MgADP and 2Pj (9) . Studies on the interaction of nitrogenase with nucleotides other than ATP indicate that 1,N6-etheno-ATP and 2'-deo_y-ATP support substrate reduction by nitrogenase (24) . Mg + has been shown to be the most effective divalent cation in substrate reduction; however, Mn2 , Fe2 , and Co2+ function to various degrees. Ca2+ is ineffective in substrate reduction (2) .
The biosynthesis of FeMo-co is a MgATP-and dinitrogenase reductase-dependent process (3, 14, 20) . It has been hypothesized that the function of dinitrogenase reductase in FeMo-co biosynthesis is analogous to its role in nitrogenase turnover in that dinitrogenase reductase performs a MgATPdependent reduction necessary for FeMo-co synthesis (14) . An in vitro system for the synthesis of FeMo-co that requires sources of at least the nifB, -N, -E, and -H gene products, molybdate, homocitrate, and MgATP, has been described elsewhere (7, 14, 20) . We have investigated the nucleotide and divalent cation requirements of the FeMo-co synthesis system and compared them with those of substrate reduction by nitrogenase to determine whether the nucleotide and divalent cation have similar roles in the two systems. Our results suggest that the role(s) of the nucleotide and divalent cation in in vitro FeMo-co synthesis is distinct from their role(s) in substrate reduction.
All nucleoside triphosphates were obtained as disodium salts landii UW45 (nifB) has been described elsewhere (8, 11) .
Growth and derepression of nitrogenase in mutant strains ofA. vinelandii hbve been previously described (18) . Preparation of crude cell extracts. Cell extracts from A. vinelandii cells were prepared by the osmotic shock method (18) . All buffers used were sparged with nitrogen, and sodium dithionite was added to a final concentration of 1.7 mM prior to use. Protein concentrations were determined by the bicinchoninic acid method, using bovine serum albumin as a standard (22) .
Partial purification of apodinitrogenase and NIFNE from A. vinelandii UW45. Apodinitrogenase (dinitrogenase that lacks FeMo-co but contains the P clusters) and NIFNE (the product of the nifN and -E genes) were partially purified from cell extracts of A. vinelandii UW45 by DEAE-cellulose anionexchange chromatography as previously described (12, 13) , with the following modification: both apodinitrogenase and NIFNE were eluted from the DEAE-cellulose column with 0.025 M Tris-HCl (pH 7.4) buffer containing 0.2 M NaCl and 20% glycerol.
In vitro FeMo-co synthesis assays. When various nucleotides were tested in in vitro FeMo-co synthesis assays, a nucleotide-regenerating system was not used since a common regenerating system is not available for all of the nucleotides tested; however, when various divalent cations were tested in the FeMo-co synthesis assay, an ATP-regenerating mixture (defined below) was used. The in vitro FeMo-co synthesis reactions were carried out in 9-ml serum vials that were sealed with serum stoppers and were repeatedly evacuated and filled with argon. The vials were rinsed with 300 ,ul of 0.025 M Tris-HCl (at pH 7.4) containing 1.7 mM dithionite (referred to NOTES as buffer A). The following components were added to the vials: 100 ,ul of buffer A, 10 ,ul of a 1.0 mM solution of Na2MoO4 in distilled water, 20 ,ul of 5.0 mM homocitrate (prepared as previously described [10] ), and 200 ,ul of a MgXTP solution (XTP is used throughout the text as a general term for the various nucleotides tested) containing 48 mM Mg2+, 24 mM XTP, and 6.3 mM dithionite. The MgXTP solutions were prepared in buffer A. The vials were incubated for 10 min at room temperature. Fifty microliters of partially purified NIFB (0.5 mg of protein) in the form of N-lauroyl sarcosine eluate (15) and 200 ,ul (3.2 mg of proteini) of desalted cell extract from strain UW45 (niJB) were then added to the reaction mixtures, which were incubated for 35 min at 30°C to allow FeMo-co synthesis and insertion into apodinitrogenase. Following the 35-min incubation, 4 pI of a 10 mM solution of (NH4)2MoS4 (in N-methylformamide) was added to the FeMo-co synthesis reactions to prevent further FeMo-co insertion into apodinitrogenase (21) . Acetylene reduction by the newly formed holodinitrogenase was then initiated by the addition of 800 ,u1 of an ATP-regenerating mixture (containing 4.2 mM ATP, 8.3 mM MgCl2, 51 mM creatine phosphate, 20 U of creatine kinase per ml, and 6.3 mM dithionite), 20 pug of purified dinitrogenase reductase (following which the vials were brought to atmospheric pressure), and 0.5 ml of acetylene (20) . Acetylene reduction was carried out for 30 min at 30°C, following which the reactions were terminated by the addition of 100 pI of 4.0 M NaOH. Ethylene formed was quantitated with a Shimadzu gas chromatograph.
When Co2+ was tested as a possible inhibitor of FeMo-co synthesis, the following modifications were made: Co2+ was added at various time points during the synthesis phase of the assay (further discussed below), and 200 plI of the ATPregenerating mixture (defined above) was added in place of MgXTP.
In Nucleotide specificity of in vitro FeMo-co synthesis. The in vitro FeMo-co synthesis assay involves the synthesis of the cofactor followed by its insertion into apodinitrogenase; the nucleotide-requiring step is the former, since the insertion of FeMo-co into apodinitrogenase from A. vinelandii UW45 (niJB) does not require the presence of a nucleotide (13) . The FeMo-co synthesis and substrate reduction activities obtained with the various nucleotides tested are compared in Table 1 . The FeMo-co synthesis system exhibits a greater stringency in its nucleotide requirement than the substrate reduction system. In vitro FeMo-co synthesis specifically requires ATP, whereas both 1,N6-etheno-ATP and 2'-deoxy-ATP function to various degrees in addition to ATP in substrate reduction, confirming the results previously reported by Weston et al. (24) . The inability of P,y-methylene-ATP (a nonhydrolyzable analog of ATP) to function in in vitro FeMo-co synthesis suggests that FeMo-co synthesis might require the hydrolysis of ATP; however, a more purified and fully characterized in vitro FeMo-co synthesis system (that is presently unavailable) would be required to address this question. The level of FeMo-co synthesis activity observed in the absence of a nucleotide is due to the inability of (NH4)2MoS4 to completely inhibit the activation of apodinitrogenase by FeMo-co that is synthesized during the acetylene reduction phase of the assay when ATP is added (21) . Since two-to fourfold-higher concentrations of ATP supported the same level of FeMo-co synthesis activity as did 8.3 mM ATP, the FeMo-co synthesis activities supported by all the other nucleotides tested are reported at this concentration (Table 1) . When the concentration of the nucleotides tested in in vitro FeMo-co synthesis was varied between 0.83 and 33.2 mM, the nucleotide specificity of FeMo-co synthesis remained as indicated in Table 1 .
Various concentrations of ADP and the ATP analogs P,-ymethylene-ATP and 2'-deoxy-ATP were tested for the ability to inhibit in vitro FeMo-co synthesis in the presence of 0.83 mM ATP (in the absence of an ATP-regenerating system). No The final concentration of M2+ in the substrate reduction assays was 4.9 mM.
inhibition of FeMo-co synthesis was observed when the ATP analogs were present in the concentration range of 0.2 to 7.5 mM (data not shown). Both ADP and 3,y-methylene-ATP inhibit nitrogenase turnover, exhibiting K1 values of 20 ,uM and 2.5 mM, respectively (23) . That ADP and ,By-methylene-ATP are ineffective as inhibitors of in vitro FeMo-co synthesis further supports the hypothesis that the role of the nucleotide in FeMo-co synthesis is distinct from its role in nitrogenase turnover.
The nucleotide specificity of the in vitro FeMo-co synthesis system and its insensitivity to analogs of ATP which inhibit nitrogenase suggest that the nucleotide might be functioning in conjunction with a component other than dinitrogenase reductase in FeMo-co biosynthesis or might be interacting with dinitrogenase reductase via a mechanism distinct from that characterized in nitrogenase turnover. Our data are in agreement with reports of altered nifH gene products which are inactive in nitrogenase turnover as a result of aberrant MgATP binding properties but which retain their ability to function in FeMo-co biosynthesis (4, 19, 25) .
The divalent cation requirement of in vitro FeMo-co synthesis. The divalent cation specificity of the in vitro FeMo-co synthesis system has also been compared with that of the substrate reduction system (Table 2) . Of the six divalent cations tested, only Mn2 , Ca2 , and Fe2+ substituted for Mg2+ to various extents in the in vitro FeMo-co synthesis assay. The level of FeMo-co synthesis activity observed in the absence of a divalent cation might be a result of the inability of (NH4)2MoS4 to completely inhibit the activation of apodinitrogenase by FeMo-co synthesized during the acetylene reduction phase of the assay (21) . Surprisingly, Ca2+ supported 50% of the FeMo-co synthesis activity observed with Mg2' but was ineffective in substrate reduction.
The FeMo-co synthesis activities obtained with Co2+ and Cu21 were lower than that observed in the absence of a divalent cation (Table 2 ). This result suggested that Co2+ and Cu2+ might be inhibitors of in vitro FeMo-co synthesis. We were specifically interested in the effect(s) of Co2+ on the in vitro FeMo-co synthesis assay because Co2+ supported low levels of substrate reduction but not FeMo-co synthesis and therefore might be useful as a specific inhibitor of FeMo-co synthesis. In the course of our studies, we found that Co2+ inhibited both FeMo-co synthesis (in the presence of 2.9 mM MgCl2) and also the insertion of preformed FeMo-co into apodinitrogenase in extracts of strain UW45 (Table 3) . We further studied the effect of Co2+ on the insertion of FeMo-co into apodinitrogenase by separately treating FeMo-co and apodinitrogenase (in extracts of strain UW45) with 0.3 mM Co2' and using the desalted components either as a source of FeMo-co or as a source of apodinitrogenase in the FeMo-co insertion assay. FeMo-co treated with Co20 was unable to activate apodinitrogenase in extracts of strain UW45; however, apodinitrogenase subjected to the same treatment remained fully activatable by FeMo-co (data not shown). Thus, one effect of Co20 on the in vitro FeMo-co synthesis assay might be the inactivation of FeMo-co itself; however, it is also possible that Co2+ inactivates a component(s) required for the biosynthesis of FeMo-co. By using an in vitro FeMo-co synthesis system consisting of purified components, the effect of Co2I on the individual components of the synthesis system might be tested.
The differences in the divalent cation specificities of the in vitro FeMo-co synthesis and substrate reduction systems suggest that a component other than dinitrogenase reductase might interact with the M2+-ATP complex in FeMo-co biosynthesis or that dinitrogenase reductase interacts with the M ATP complex via a mechanism other than that established for nitrogenase turnover. The observed differences might also be the result of a divalent cation requirement independent of the nucleotide requirement for the in vitro FeMo-co synthesis system; however, at present we are unable to separate the nucleotide and divalent cation requirements.
The ATP-requiring step(s) in the biosynthesis of FeMo-co has not been identified. Once the individual components of the FeMo-co synthesis system have been purified and fully characterized, we will be able to identify the component(s) in the FeMo-co biosynthetic pathway that interacts with ATP and also determine whether the hydrolysis of ATP is necessary for the biosynthesis of FeMo-co. The role(s) of the divalent cation in FeMo-co synthesis might also become clear when a purified in vitro synthesis system is used. The determination of the nucleotide and divalent cation specificity of in vitro FeMo-co synthesis provides further insight into the processes involved in the biosynthesis of the cofactor and provides a framework for future studies investigating the role of the nucleotide and divalent cation in FeMo-co biosynthesis.
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